🔗 Visit the ClinicalTrials.gov page for NCT00570713
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers. | Clin Cancer Res | 2010 | 1.59 |
| 2 | Discovery of mesothelin and exploiting it as a target for immunotherapy. | Cancer Res | 2014 | 1.48 |
| 3 | Mesothelin-targeted agents in clinical trials and in preclinical development. | Mol Cancer Ther | 2012 | 1.47 |
| 4 | Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors. | Cancer Discov | 2015 | 1.18 |
| 5 | Specificity delivers: therapeutic role of tumor antigen-specific antibodies in pancreatic cancer. | Semin Oncol | 2014 | 0.79 |